Wilsons analyst Shane Storey maintained a Hold rating on Next Science Ltd (NXSCF – Research Report) on July 28 and set a price target of A$0.56. The company’s shares closed last Friday at $0.39.
According to TipRanks, Storey is a 4-star analyst with an average return of 15.1% and a 54.79% success rate. Storey covers the Healthcare sector, focusing on stocks such as Impedimed Limited, Telix Pharmaceuticals Ltd., and Ramsay Health Care.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Next Science Ltd with a $0.47 average price target.
See today’s best-performing stocks on TipRanks >>
NXSCF market cap is currently $79.98M and has a P/E ratio of -6.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Next Science Ltd is an Australia based company formed to commercialise and develop its Xbio technology, which is a non-toxic technology with efficacy in eradicating both biofilm based and free-floating bacteria. The company’s products includes SurgX Sterile wound Gel, Bactisure Surgical Lavage and Blast X Wound Gel.
